Стенограммы и видео от ведущих зарубежных онкологов
Download this brief resource with clinical pearls related to testing and targeted treatment for BRAF V600E–mutant mCRC and mNSCLC.
Download these slides from a recent educational program to determine optimal subcutaneous immunotherapy strategies and improve clinical outcomes for patients with solid tumors.
Enhance your knowledge and optimize treatment for patients with R/R MM by learning from subject matter experts Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, in this podcast. Listen as they discuss various strategies to optimize the use of bispecific antibodies in their practices through patient monitoring, dosing in outpatient settings, and utilizing tocilizumab and IVIG among other management strategies.
Experts answer your questions related to the program, “Beyond CIT: Uniting Patient Voices With the Latest Evidence on Novel Targeted Therapies for CLL/SLL.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.
In this commentary, disease experts discuss how optimizing clinical processes, including biomarker testing workflows, treatment sequencing, toxicity management, and multidisciplinary coordination, can improve the safe and effective use of immunotherapy for patients with advanced NSCLC.
Experts answer your questions related to the program, “Beyond Resistance: Integrating Next-Generation SERDs into Community Management of ER-Positive/HER2-Negative Advanced Breast Cancer.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.
Download these slides from a recent educational program on novel emerging strategies to improve the management of patients with multiple myeloma.
In this commentary, an expert addresses key questions on evolving frontline therapy strategies, counseling patients about stem cell transplant, and individualizing treatment decisions in multiple myeloma.
In this expert commentary, the evolving landscape of mCRPC is examined, with a focus on the biological rationale, clinical evidence, and implementation challenges of novel targeted therapies and precision medicine approaches.
Downloadable slides on best practices for anti-CD38–based treatments for smoldering and newly diagnosed multiple myeloma, including risk stratification, emerging clinical trial data, and transplant-eligible therapy approaches.
Download this slideset on thrombosis in myeloproliferative neoplasms, including key risk factors, predictive scoring systems, and the role of JAK2 mutations. Learn how these factors inform clinical decision-making and evidence-based strategies for preventing and managing arterial and venous thrombotic events
Review this text module to gain expert insight into the complex mechanisms driving thrombosis in myeloproliferative neoplasms, including key risk factors, predictive scoring systems, and the role of JAK2 mutations. Learn how these factors inform clinical decision-making and evidence-based strategies for preventing and managing arterial and venous thrombotic events.
Expert commentary on the evolving role of antibody–drug conjugate use in patients with relapsed/refractory DLBCL, including answers to frequently asked questions from a live webinar audience of healthcare professionals with a focus on patient selection, clinical integration, management challenges, and future directions within an increasingly complex treatment landscape.
Experts answer your questions related to the program, “The Art of Therapeutic Balance: Innovations in Pancreatic Cancer Across the Disease Continuum.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.
The PDF/downloadable resource is intended to be used by healthcare providers and their eligible patients to highlight and communicate the reasons for recommending low-dose CT screening to detect lung cancer.
Download slides from a live webinar to gain global expert perspectives on molecular testing and perioperative immunotherapy and targeted therapy for early-stage NSCLC.
Experts answer your questions related to the program, “The Next Frontier for CDK4/6 Inhibitors in Breast Cancer: Expert Strategies for Applying the Latest Guidelines and Advances in Practice.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.
Read this commentary detailing the results of a survey of healthcare professionals on managing patients with essential thrombocythemia (ET) and polycythemia vera (PV). Then review the expert-authored text modules, podcasts, and downloadable resources to close these gaps and improve patient outcomes.
Download this short resource for your patients with BRAF V600E–mutant metastatic CRC or NSCLC to help them understand their disease and potential treatment options, and provide useful questions to help individualize care decisions to their goals.
Download this brief resource with clinical pearls related to the management of adverse events related to targeted therapy for BRAF V600E–mutant mCRC and mNSCLC.